Qualitative Concept – Page 27

AstraZeneca details $2.5B investment in China’s political center, funding R&D center, biotech pacts

6 months ago talkbio0Tagged AstraZeneca, Beijing, China, China 's, Collaboration, Investments

Investments, AstraZeneca, Beijing, China, China ‘s, Collaboration

Johnson & Johnson Announces $55 Billion Investment in U.S. Manufacturing and Innovation

6 months ago talkbio0Tagged aligns, announcement, Benefit, capabilities, commitment, Corporation, domestic pharmaceutical industry, Increased, innovation, Investments, J&J 's, Manufacturing, Surgical construction, trends qualifier, United States

This major investment demonstrates J&J’s commitment to expanding its U.S. manufacturing and innovation capabilities, with potential benefits for job creation and the domestic pharmaceutical industry. The announcement aligns with broader trends of increased U.S. manufacturing investment by large corporations in recent years.

Alnylam’s Amvuttra Approved for ATTR Cardiomyopathy, Challenging Pfizer and BridgeBio

6 months ago talkbio0Tagged Amvuttra, Approved, ATTR-CM, Cardiomyopathies, RNA Interference, United States Food and Drug Administration

Amvuttra, vutrisiran, ATTR-CM, FDA approval, RNAi therapeutic, cardiomyopathy

Adaptimmune, after bringing cell therapy to market, questions viability and defunds 2 preclinical programs

6 months ago talkbio0Tagged Adaptimmune, cellular targeting, Market, Solid Neoplasm, Tecelra, Viable

Adaptimmune, Tecelra, Viable, Market, Solid Neoplasm, cellular targeting

A closer look at pharmas top patent losses in 2025

6 months ago talkbio0Tagged 2023, 2025, Bayer, competition, Expiration, function, Impact food supplement, Indication of (contextual qualifier), Legal patent, Market, Patent Cliff, Regeneron, Sales - occupational activity

Legal patent, Expiration, function, Market, Indication of (contextual qualifier), competition, Impact food supplement, Sales – occupational activity, Bayer, 2025, patent cliff, Regeneron, 2023